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Abstract: Breast cancer is a major cause of cancer-related deaths among older women, aged 
65 years or older. Screening mammography has been shown to be effective in reducing breast 
cancer mortality in women aged 50–74 years but not among those aged 75 years or older. Given 
the large heterogeneity in comorbidity status and life expectancy among older women, contro-
versy remains over screening mammography in this population. Diminished life expectancy 
with aging may decrease the potential screening benefit and increase the risk of harms. In this 
review, we summarize the evidence on screening mammography utilization, performance, and 
outcomes and highlight evidence gaps. Optimizing the screening strategy will involve separat-
ing older women who will benefit from screening from those who will not benefit by using 
information on comorbidity status and life expectancy. This review has identified areas related 
to screening mammography in older women that warrant additional research, including the 
need to evaluate emerging screening technologies, such as tomosynthesis among older women 
and precision cancer screening. In the absence of randomized controlled trials, the benefits and 
harms of continued screening mammography in older women need to be estimated using both 
population-based cohort data and simulation models.
Keywords: aging, breast cancer, precision cancer screening
Introduction
Globally, breast cancer is the most commonly occurring cancer among women, 
comprising 23% of the ~1.7 million female cancers that are newly diagnosed each 
year.1,2 Approximately 6.2 million women were diagnosed with breast cancer in the 
last 5 years, making breast cancer the single most prevalent cancer around the globe.1 
In the USA, breast cancer is responsible for most new cases of cancer among women 
with an estimated 29% of new cancer cases and 14% of cancer deaths in 2014.2 
Approximately 41% of all incident breast cancers and 57% of all breast cancer deaths 
occur among women aged 65 years and older.3
The incidence of breast cancer in the USA generally increases until 80 years of 
age, at which point the incidence begins to decrease, possibly due to lower rates of 
screening, the mammographic detection of cancers before 80 years of age, or incom-
plete detection.4 Screening mammography, the only population-based method for the 
early detection of breast cancer, has been shown to be effective in reducing breast 
cancer mortality in women aged 50–74 years.5,6 Yet, there is no evidence regarding 
the effectiveness of screening mammography in women aged 74 years and older. 
Diminished life expectancy that occurs with aging decreases the probability of a screen-
ing benefit and likely increases the risk of harms.7 Because of large heterogeneity in 
comorbidity status and life expectancy among older women, aged 65 years or older, 
a continuing controversy exists over screening mammography in this population.8,9 
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The consequences of screening older women have not been 
well described, especially in relation to life expectancy. 
Randomized trials of screening mammography cannot pro-
vide the evidence because the trials excluded women older 
than 75 years and those with significant comorbidity.10
The impact of new imaging technologies on screening 
mammography outcomes in older women is not well under-
stood. Although routine screening with two-dimensional 
(2D) digital mammography is the primary means of 
early breast cancer detection, the use of newer imaging 
technologies, such as digital breast tomosynthesis (DBT, 
also referred to as 3D mammography) is diffusing rapidly 
into clinical practice.11 In recent studies, the addition of 
DBT to 2D digital mammography resulted in a decrease 
in recall rates and an increase in cancer detection rates, 
when compared with 2D digital mammography alone.12–17 
Given that these findings point to significant improvements 
in breast cancer screening outcomes with DBT, it will be 
important to include women in older age ranges in future 
studies of DBT.
In this review, we summarize the evidence and current 
perspectives regarding the utilization of screening mam-
mography and performance and outcomes in older women 
and highlight evidence gaps in this field.
Screening mammography utilization 
in older women
Several guidelines support screening mammography in older 
women unless a woman’s comorbid conditions limit life 
expectancy (Table 1). In women aged 70 years and older, the 
World Health Organization recommendation only specifies 
that well-resourced settings with the infrastructure to create 
population-based programs should provide screening.18 The 
US Preventive Services Task Force (USPSTF) updated their 
guidelines in 2009 to recommend biennial, rather than yearly 
screening mammography until 74 years of age but concluded 
that evidence was insufficient to make recommendations for 
women aged 75 years and older.10,18 Recently revised breast 
cancer screening recommendations from the American 
Cancer Society (ACS) are for regular screening mammogra-
phy for women at an average risk of developing breast cancer 
beginning at 45 years of age and continuing after 70 years of 
age amongst women who are in good health.19 The National 
Cancer Institute is reevaluating its past recommendations in 
light of the USPSTF recommendations and supporting further 
research.10 Both the ACS and the USPSTF guidelines state 
that screening in older women should be considered on an 
individual basis through the evaluation of potential benefits 
and risks posed by the mammogram in relation to their current 
health conditions and predicted life expectancy.
In the USA, screening mammography attendance rates 
among older women are generally high. For example, ~73% of 
US women aged 75 years or older reported having undergone 
screening mammography in the 2010 US Behavioral Risk 
Factor Surveillance System in the last 2 years.20 According 
to data from the 2013 National Health Interview Survey, 
75.3% of women aged 65–74 years and 56.5% of women aged 
75 years and older self-reported screening mammography 
use in the last 2 years.21 Crucially, screening mammogra-
phy is also commonly reported among older US women in 
poor health in the National Health Interview Survey22–24 and 
in the US Breast Cancer Surveillance Consortium.25 Thus, 
many older women undergo screening mammography without 
evidence of benefits from screening.
Screening mammography utilization 
by comorbidity and functional status
In older women, comorbid conditions and diminished life 
expectancy may influence a physician’s decision to recom-
mend mammography or a woman’s decision to undergo 
screening.26,27 Table 2 provides a summary of studies that 
evaluated the association between comorbidity and screening 
mammography utilization. Several of the studies evaluating 
comorbidity and screening utilization reported that a higher 
Table 1 Guideline recommendations about screening mammography in older women
USPSTF guidelines ACS guidelines ACR guidelines AGS guidelines
Offer biennial screening to 
women aged 50–74 years. 
Evidence is insufficient to 
recommend for or against 
screening in women .74 years 
of age. “I” statement*. The 
Task Force encourages more 
research on the topic.
Offer screening to women 
aged $45 years and 
continue as long as a woman 
is in good health and has life 
expectancy of $10 years.
Offer annual screening to 
women aged $40 years  
and continue as long as a 
woman is in good health.
Offer screening to women aged #85 years 
who have life expectancy of $5 years and 
for healthy women aged $85 years who 
have excellent functional status or who feel 
strongly about the benefits of screening 
(no screening frequency specified).
Notes: *Current evidence is insufficient to address benefits and harms of breast cancer screening in women .74 years of age.
Abbreviations: ACR, American College of Radiology; ACS, American Cancer Society; AGS, American Geriatrics Society; USPSTF, US Preventive Services Task Force.
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Charlson comorbidity score was associated with lower 
screening utilization.28–31 For example, women with Charlson 
scores of $2 were found to have a 35% reduction in the odds 
of mammography utilization (odds ratio [OR]: 0.65, 95% 
confidence interval [CI]: 0.58–0.72).30 Conflicting evidence 
exists regarding the impact of the total number of comorbid 
conditions on screening use, with two studies finding that 
higher numbers of comorbid conditions increased screening 
mammography utilization,32,33 whereas two other studies 
reported an inverse association.34,35 This variance may reflect 
the use of different sums of comorbid conditions.
Studies evaluating the associations between cognitive 
impairment, depression, and screening mammography uti-
lization have generally shown inconclusive results (Table 2) 
In a study of Mexican American women aged 75 years and 
older that measured cognitive impairment (using the mini-
mental state examination [MMSE]), lower MMSE scores 
were associated with decreased odds of screening utilization 
(OR: 0.62, 95% CI: 0.45–0.86).36 Moreover, the same study 
reported that increased depressive symptoms, as reflected 
by the Center for Epidemiological Studies-Depression 
(CES-D) scale, were associated with increased screening 
mammography utilization.36 However, other studies measur-
ing cognitive impairment with MMSE and depression with 
CES-D scale in more diverse populations found equivocal 
results.32,33,35,37,38
Studies of functional limitations have generally found 
an inverse association with screening utilization (Table 2). 
Specifically, activities of daily living (ADL) limitations 
were associated with decreased screening mammography 
utilization,22,37–40 with one study in 2003 finding more sig-
nificant decreases in utilization in women older than 70 years 
(OR: 0.18, 95% CI: 0.07–0.44).40 Similar results were 
found with instrumental activities of daily living (IADL) 
limitations,32,36,38,40 since long-term IADL limitations – 
identified by reporting limitations at both visits – were more 
strongly associated with decreased mammography utilization 
(OR: 0.40, 95% CI: 0.22–0.73).40 When considering scales 
using both ADL and IADL measurements, having severe 
limitations led to significant decreases in odds of screening 
mammography.29,33,34
In general, women’s perceptions of their general health 
were not statistically significant predictors of change in 
screening mammography utilization (Table 2). Of the 
seven studies measuring perceived general health in older 
women,29,33,37,41–44 only two found a significant positive 
association between declining perceived health status and 
screening mammography utilization.33,42 Life expectancy 
measured by a prognostic index was a strong predictor of 
screening mammography utilization in older women, with 
four studies indicating that women with a higher risk of 
mortality had lower odds of screening mammography.39,43,45,46 
Notably, Koya et al found a nearly 80% decrease in odds of 
mammography utilization in women in the lowest life expec-
tancy group (OR: 0.22, 95% CI: 0.13–0.36).43 Moreover, 
in a study that used a life expectancy index with income 
as a stratifying covariate, women with higher incomes and 
longer life expectancy (relative risk [RR]: 1.18, 95% CI: 
1.05–1.32) or higher incomes and limited life expectancy 
(RR: 1.92, 95% CI: 1.20–3.09) had increased utilization 
of screening mammography than their counterparts with 
lower incomes.47
There is paucity of data examining the association between 
comorbidity or life expectancy and screening mammography 
utilization in older women outside of the USA. Of note, 
many of the aforementioned studies employed as the main 
outcome claims (or health insurance-derived) data30,31,37–39,46,48 
or self-reported mammography utilization,32–34,40,42,44,45,47,49 
with the latter being more likely to result in potentially biased 
effect estimates.
In summary, there is compelling evidence that older 
women with a greater comorbidity burden and poorer 
functional status are less likely to undergo screening mam-
mography, particularly among studies that employed stan-
dardized comorbidity measures.28–31 Moreover, diminished 
life expectancy was also found to be inversely associated 
with mammography utilization.39,43,45,46 Although perceived 
general health was found to be an inconclusive predictor 
of screening utilization,29,33,37,41–44 further research on the 
impact of life expectancy indicators may enhance our 
understanding of screening mammography utilization in 
older women.
Screening mammography 
performance in older women
Overall, there is limited evidence regarding screening 
mammography performance in older women. Hitherto, two 
studies have explicitly examined screening mammography 
performance in older US women.50,51 A 2011 study by 
Sinclair et al evaluated the accuracy and cancer detection rate 
among 403,448 mammograms (the majority of which were 
captured with film-screen mammography) for women aged 
50–101 years living in Vermont.50 Interestingly, screening 
mammography performance improved with age in this study; 
when compared to women aged 50–59 years, those aged 
70–79 years had an increase in sensitivity (77.3%–80.4%), 
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specificity (98.7%–99.0%), positive predictive value 
(22.2%–37.6%), and cancer detection rate (3.7/1,000– 
6.2/1,000 mammograms).50 The relationship between age 
and performance measures was not influenced by potential 
confounders of body mass index, breast density, education, 
race, ethnicity, family history of breast or ovarian cancer, 
personal history of ovarian cancer, current or prior use of 
hormone therapy, and age at menopause or menarche.
The second study in USA, published in 2015, utilized the 
national Breast Cancer Surveillance Consortium data from 
296,496 full-field digital screening mammograms among 
women aged 65 years and older to assess performance.51 
Of note, the performance measures in this study were also 
stratified by the Breast Imaging Reporting and Data Systems’ 
breast density values to determine if breast density rather 
than age was affecting mammography performance. Similar 
to the 2011 study, the specificity, positive predictive value, 
and cancer detection rate of digital screening mammography 
improved significantly with increasing age. In contrast to the 
2011 study,50 the sensitivity of digital screening mammog-
raphy did not increase with age and was 88.3% overall. The 
recall rate, which was not examined in the earlier study,50 
decreased significantly from 8.4% (95% CI: 7.8%–8.0%) in 
women aged 65–69 years to 7.3% (95% CI: 6.9%–7.8%) in 
women aged 85 years and older. Adjusted models showed 
similar improvements with increased age, suggesting that 
both age and breast density impact the recall rate, specificity, 
positive predictive value, and cancer detection rate. Of note, 
this study evaluated digital mammography because of its 
widespread utilization in the USA and did not consider film 
mammography; the cost-effectiveness of digital mammog-
raphy compared to film mammography in older women has 
not been established.52
Because screening mammography programs outside the 
USA do not typically include women older than 70 years or 
74 years, there is limited evidence on the performance of 
screening mammography at the 5- or 10-year age-groups 
necessary to evaluate performance in older women. The 
Ontario Breast Screening Program that includes women 
aged 50–59 years, 60–69 years, and 70–74 years and reports 
performance measures for these groups reported significant 
increases in cancer detection rate (CDR) and positive predic-
tive values with increasing age, and a significant decrease in 
the recall rate with increasing age.53
Results from both US studies50,51 show that as age 
increased, the proportion of invasive versus ductal carcinoma 
in situ (DCIS) cases increased, with the exception of women 
aged 90–101 years in the Vermont study; approximately 
75%–81% of cancers detected in older women were inva-
sive. In both studies,50,51 the proportion of cases with posi-
tive nodes decreased with increasing age. Tumors detected 
in the era of film-screen mammography showed a positive 
association of age and estrogen receptor-positive status, 
with the proportion of estrogen receptor-positive increas-
ing with increasing age.51 However, in the digital screening 
era, as age increased, the proportion of lower grade tumors 
increased.52 Neither study found a significant association 
of tumor stage with age.50,51 Moreover, a study by Smith-
Bindman et al in 2000 found that women aged 66–79 years 
who underwent screening mammography had a decreased 
risk of detecting metastatic breast cancer.54 Of note, neither 
of these aforementioned studies examined screening mam-
mography performance in the context of comorbidity or life 
expectancy.50,51
Screening mammography outcomes 
in older women
Since rates of clinically indolent tumors and DCIS increase 
with age, older women are more likely to be harmed from 
overdiagnosis,55 defined as detection of tumors by screening 
that would not become clinically apparent during a woman’s 
lifetime or would not affect overall survival. Given the 
steeper rise in competing causes of mortality in women older 
than 74 years, evidence suggests that rates of overdiagno-
sis are likely to be greater for older women than younger 
women.55,56 Screening tests can have immediate harmful 
consequences and the long-term benefits of screening may 
not be realized in women with a short life expectancy.26,27,57–59 
The most important benefit of screening mammography in 
older populations is an improvement in life expectancy, while 
the harms include false-positive results and overdiagnosis.7 
Given the increasing comorbidity burden and attendant 
decline in life expectancy, some older women are unlikely 
to have a favorable benefit/harm ratio.58,60
The currently available evidence regarding the impact 
of comorbidity and health status on screening mammogra-
phy outcomes consists of four observational25,61–63 and three 
decision models64–66 because no randomized trials included 
women older than 74 years. It is important to recognize that 
observational data are subject to selection bias as well as 
lead-time and length bias. In observational studies evalu-
ating screening mammography, the study populations of 
older women have self-selected to undergo screening mam-
mography and are likely to be healthier than the general US 
population.64–66 Both cohort studies and decision analytic 
models25,61–66 found that screening benefits decreased with 
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increasing age and comorbidity burden. Thus, the balance of 
benefits versus harms varies according to comorbidity and 
age, which underscores the need for evidence to develop life 
expectancy-based screening strategies.
Benefits of screening mammography 
in older women
Only one cohort study has so far evaluated mortality as 
a benefit of breast cancer screening.63 In the study by 
McPherson et al,63 which included 5,186 women aged 
65 years and older diagnosed with breast cancer between 
1986 and 1994 through the Upper Midwest Tumor Registry 
system, women’s comorbidity was assessed via the Charlson 
score.67 In this study, women aged 65 years and older with 
no or moderate comorbidity and mammographically detected 
tumors were found to be at reduced risk of breast cancer death 
compared to those with clinically detected tumors (Table 3).63 
In addition, among women with severe comorbidity, as 
defined by a Charlson score of $3, screening mammography 
was associated with reduced breast cancer mortality among 
women aged 70–74 years, but not in those younger than 
70 years or older than 74 years.63
Although detection of early stage disease at diagnosis 
has been utilized as a marker of screening benefit, this may 
not necessarily represent a benefit in older women with 
indolent tumors. Of the three cohort studies that evalu-
ated the risk of early versus advanced tumor stage,25,61,62 
two – Braithwaite et al61 and Yasmeen et al25 – used data 
from the US Breast Cancer Surveillance Consortium linked 
to Medicare insurance claims data from 1999 to 2006, to 
evaluate comorbidities in the 2 years before screening mam-
mography. In another cohort study, Fleming et al merged 
data from the Surveillance, Epidemiology and End Results 
program with Medicare insurance claims for 17,468 women 
diagnosed with breast cancer between 1993 and 1995.62 Het-
erogeneous measures of comorbidity were utilized in these 
three studies: Braithwaite et al61 employed the Charlson 
comorbidity score while Fleming et al62 and Yasmeen et al25 
reported on 24 individual conditions, and severity-based 
categorizations of comorbidity, respectively. Yasmeen 
et al found that overall rates of advanced breast cancer 
(per 1,000 mammograms) were lower among women with 
no comorbidity than among those with stable comorbidity 
in annually and biennially screened women and for those 
that received their first screen (Table 3).25 However, among 
women who had prior mammography within 4–18 months 
of cancer diagnosis, the rates of advanced-stage cancer 
were higher among those with either stable or unstable 
comorbidities than among those without comorbidities.25 
In contrast, Braithwaite et al61 reported that adverse tumor 
characteristics, including advanced stage, did not differ 
significantly by the Charlson score or screening interval. 
Moreover, Fleming et al62 reported that women with car-
diovascular disease, musculoskeletal disorders, mild-to-
moderate gastrointestinal disease, and nonmalignant benign 
breast disease had a 13%, 7%, 14%, and 24% lower odds, 
respectively, of being diagnosed with advanced breast 
cancer, while those with diabetes, other endocrine disor-
ders, psychiatric disorders, and hematologic disorders had 
increased odds of advanced stage diagnosis by 19%, 11%, 
20%, and 19%, respectively, compared to women without 
these comorbidities.
Consistent with observational data, decision analyses 
confirm that women aged 65 years or older are less likely 
to benefit from screening, particularly if they have severe 
comorbidity,68 and propose a comorbidity-dependent 
cessation age.65 Moreover, another decision analytic model 
reported minimal quality-adjusted life expectancy for women 
aged 85 years and older with average health or mild comor-
bidity and losses in quality-adjusted life expectancy for 
women with severe comorbidity.64 Specifically, two decision 
analyses, Mandelblatt et al68 and Lansdorp-Vogelaar et al,65 
employed well-established, independently developed Cancer 
Intervention and Surveillance Modeling Network models, 
with each model simulating the life histories of large US 
cohorts, and assessing the underlying disease in the presence 
and absence of screening. Relative life expectancy benefits 
of screening in older women according to comorbidity are 
shown in Table 3. In particular, Lansdorp et al compared 
the number needed to screen per life-year gained at differ-
ent stopping ages and estimated threshold stopping ages 
according to the level of comorbidity, at which the num-
ber needed to screen per life-year gained was the same as 
that of mammography until 74 years of age for women of 
average comorbidity.65 Authors evaluated biennial screen-
ing mammography from 50 years of age to a cessation 
age ranging from 66 years to 90 years by simulating US 
cohorts of women who were 66–90 years old and alive in 
2010, and had no comorbidity, mild comorbidity (a history of 
myocardial infarction, acute myocardial infarction, ulcer, or 
rheumatologic disease), moderate comorbidity (the presence 
of vascular disease, cardiovascular disease, paralysis or, dia-
betes), or severe comorbidity (the presence of AIDS, mild or 
severe liver disease, chronic obstructive pulmonary disease, 
chronic renal failure, dementia, or congestive heart failure), 
as well as comparison cohorts of average comorbidity aged 
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74 years and 76 years. In this study, Lansdorp et al found that 
breast cancer screening through 74 years of age resulted in a 
number needed to screen to gain 1 life-year among women 
with no comorbidity of 117–149 across models, which was 
lower than that in the entire population with average comor-
bidity; cessation of screening at 76–78 years of age among 
women with no comorbidities was estimated to yield the same 
number needed to screen to gain 1 life-year as cessation at 
74 years of age in the entire population.65 Finally, this study 
points to the benefits of biennial mammography across models 
until median ages of 76–78 years, 74 years, 70–72 years, and 
64–68 years for women with no comorbidity, mild comorbid-
ity, moderate comorbidity, and severe comorbidity, respec-
tively.65 In hypothetical cohorts examining benefits of biennial 
screening in terms of life-years, Mandelblatt et al64 found that 
long- and short-term quality-adjusted savings in life expec-
tancy from screening compared to a nonscreening strategy 
were greater for older women with mild hypertension than 
for those with heart disease, and the benefit in both groups 
decreased with increasing age (Table 3). Finally, in another 
decision analysis examining three hypothetical cohorts of 
women aged 75–79 years, 80–84 years, and $85 years with 
and without cognitive impairment, Messecar tested the gain 
in quality-adjusted life-years in two models for each group 
assuming no prior screening versus continued biennial screen-
ing. In this study,66 all older women benefited from biennial 
screening mammography, although among women with no 
prior screening, the gain in quality-adjusted life-years was 
lower among cognitively impaired women (20 days, 9.1 days, 
and 5.5 days for age-groups 75–79 years, 80–84 years, 
and $85 years, respectively) than their healthy counter-
parts (43.4 days, 32.5 days, and 25.9 days for age-groups 
75–79 years, 80–84 years, and $85 years, respectively).66
The aforementioned benefits should be considered in con-
junction with reported harms of screening in older women.
Harms of screening mammography 
in older women
There are evidence gaps regarding the harms of screening 
mammography in older women according to comorbidity and 
life expectancy;61,65 a summary of studies that have hitherto 
addressed this question is shown in Table 3. In the US Breast 
Cancer Surveillance Consortium cohort study that evaluated the 
harms of screening mammography, Braithwaite et al reported 
that the 10-year cumulative probability of a false-positive 
mammography result was higher among annual screeners 
than biennial screeners irrespective of comorbidity: 48.0% 
(95% CI: 46.1%–49.9%) of annual screeners aged 66–74 years 
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had a false-positive result compared with 29.0% (95% CI: 
28.1%–29.9%) of biennial screeners.61 In a decision-analytic 
study evaluating the harms of screening, Lansdorp-Vogelaar 
et al65 showed that ending screening at 74 years versus 72 years 
of age resulted in 96 more false-positive tests and 0.5 more 
overdiagnoses per 1,000 screening tests (Table 3). In examin-
ing the balance of benefits versus harms from screening mam-
mography, Lansdorp-Vogelaar et al65 also assessed numbers 
needed to screen in relation to life-years gained and estimated 
that extending breast cancer screening from the age of 72 years 
until 74 years of age among individuals with average comor-
bidity, required screening 132–174 women to gain 1 life-year; 
continuing screening until 76 years of age required an additional 
146–198 women to be screened to gain 1 life-year.65
Another simulation model indicated that personalized 
screening based on individual risk that is measured as a func-
tion of age, breast density, history of breast biopsy, family 
history of breast cancer, and screening interval could poten-
tially improve the balance of benefits versus harms among not 
only older but also younger women, where low-risk women 
could stop screening or continue to be screened at longer 
intervals, thereby reducing false-positive results.69
Decision-making regarding 
screening mammography among 
older women
Communication about potential benefits and harms to 
older women in their 70s and 80s also poses a challenge, 
given the limited available evidence.7,60,70–72 In light of this 
uncertainty, clinical decisions about undergoing mam-
mography in older populations would likely benefit from 
adopting life expectancy-based screening. A recent meta-
analysis of survival data from population-based, randomized 
controlled trials comparing populations screened and not 
screened for breast cancer reported that it took 10.7 years 
(4.4–21.6 years) on average across included studies, before 
one death from breast cancer was prevented for 1,000 
women screened; hence, this study concluded that screening 
for breast cancer should be targeted to women with a life 
expectancy .10 years.57 To this end, it will be important for 
primary care physicians to adopt prognostic tools that provide 
estimates of women’s risk of 10-year mortality,73 since such 
tools may facilitate informed decisions about screening.
A prognostic tool developed by Cruz et al73 based on data from 
the Health and Retirement Survey, a nationally representative 
cohort of community-dwelling US adults .50 years, is a 
12-item mortality index that calculates an estimate of 10-year 
mortality based on age, sex, tobacco use, body mass index, 
diabetes, nonskin cancer, chronic lung disease, heart failure, 
and ADL (difficulty bathing, difficulty managing finances, dif-
ficulty walking several blocks, and difficulty pushing/pulling 
objects, etc). Application of valid prognostic tools in primary 
care settings may identify women with a low versus high risk 
of 10-year mortality that would and would not benefit from 
screening mammography, respectively. Recently developed 
decision aids show promise for counseling older women about 
the benefits and harms of screening mammography74 and may 
help overcome the challenges of implementing life expectancy-
based screening strategies in clinical practice.
Conclusion and future directions
In summary, screening mammography may be beneficial to 
older women if they have life expectancy of at least 10 years. 
Optimizing the screening strategy will involve a careful balance 
of benefits versus harms and life expectancy-based screening 
strategies. While the balance of benefits versus harms may be 
favorable for women up to 69 years of age and perhaps even up 
to 74 years of age with biennial screening, there is little evidence 
to support annual screening in older populations. Consistent 
with this, the updated USPSTF guidelines recommend biennial 
screening for women aged 66–74 years, but there are no explicit 
recommendations for women aged 75 years and older because of 
insufficient evidence. To better target populations who will ben-
efit from screening, the National Cancer Institute has launched a 
new precision-based cancer screening initiative.75 With the aging 
of the population, it will be increasingly important to evaluate life 
expectancy-based screening by identifying women with sufficient 
life expectancies to benefit from screening, while minimizing 
harms associated with false-positive results and overdiagnosis 
among women who will not live long enough to benefit.
This review has identified many areas related to screening 
mammography in older women that need additional research. 
For example, there is a paucity of research evaluating emerg-
ing screening technologies such as tomosynthesis among 
older women. Without randomized controlled trials, the 
benefits and harms of continued screening mammography in 
older women will need to be estimated using a combination 
of cohort data and simulation models.
As pointed out in the recent JNCI editorial,76 direct appli-
cation of simulation models to the breast cancer screening 
policy and clinical practice remains a challenge. To address 
this gap and eschew the pseudoprecision that modeling can 
portray,76 it will be important to combine empirical evidence 
with modeling. Moreover, moving the field forward will 
necessitate modeling screening performance and mortality 
as a function of comorbidity, cognitive/physical functioning, 
Clinical Interventions in Aging 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
124
Braithwaite et al
and life expectancy as well as cost-effectiveness of different 
screening strategies according to these factors.
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